Robert M. Rifkin

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Shaji Kumar, Ian W. Flinn, Paul G. Richardson et al. · Blood · 2012 · 451 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Fredrik Schjesvold, Albert Oriol, Lionel Karlin et al. · The Lancet Haematology · 2019 · 242 citations · Full text

Medicine, Oncology, Pharmacology +11

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus et al. · New England Journal of Medicine · 2024 · 166 citations

Medicine, Pharmacology, Pharmacotherapy +13

High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study

Raymond B. Weiss, Robert M. Rifkin, F. Marc Stewart et al. · The Lancet · 2000 · 163 citations

Medicine, Oncology, Breast Oncology +6

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Rubén Niesvizky, Ian W. Flinn, Robert M. Rifkin et al. · Journal of Clinical Oncology · 2015 · 152 citations

Medicine, Pharmacology, Pharmacotherapy +14